FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for FY 2022

Summary

The US Food and Drug Administration (FDA) has set the fee rate for using a rare pediatric disease priority review voucher for fiscal year 2022, based on the average costs incurred by the agency to review human drug applications in the previous year.